Healthtech startup Emerald raises £700k backed by Innovate UK and Sequel
This article covers Emerald, a healthtech startup, and its closing of a seed funding round of £700k as part of a £1.4m package that combines a £700k Innovate UK grant with matched venture investment. The funding is intended to accelerate commercial roll-out and AI development for its preventative screening platform and expand distribution through employer and consumer partnerships, targeting employers, benefits providers and users of UK healthcare services.
Emerald, a healthtech startup, has closed a seed funding round of £700,000, part of a larger £1.4 million fundraising that combines a £700,000 Innovate UK grant with a matched £700,000 in venture investment. The injection raises Emerald’s total funding to £2.9 million and arrives as the company scales its preventative screening platform and expands distribution through employer and consumer partnerships.
Why it matters
Emerald positions itself at the intersection of early detection and ongoing care, a gap the NHS and private sector alike are trying to address. The fresh finance is intended to accelerate commercial roll-out and development of the platform’s AI capabilities — a priority for both the company and public funders — and could affect how routine screening and follow-up are embedded into employee benefits and consumer health journeys.
Inside the product
Emerald combines in-clinic laboratory screening with a digital platform that aggregates test results, wearable data and health history, and pairs each member with a GP who can diagnose, prescribe and refer into private or NHS care. The company is clinician-founded, Care Quality Commission registered and authorised as a UKCA Class I medical device with the MHRA.
Since the start of 2026, Emerald reports a tenfold increase in members and more than 100,000 laboratory tests processed. The company cites repeat-screening data that indicates improvements for members: two out of three showed better cholesterol levels, average blood sugar readings fell by about a third, and markers of inflammation decreased by nearly half. These figures are presented as company-reported outcomes from its screening and follow-up programme.
Distribution has grown via partnerships with Pluxee, Epassi and Yonder, among others, enabling employers and benefits providers to offer Emerald’s screening and care pathway to employees and customers. Pluxee and Epassi are known for employee benefits and fintech integrations, while Yonder operates in fitness and consumer wellbeing; each partnership expands Emerald’s route to market and recurring revenue opportunities.
Who are the investors?
The £1.4 million package comprises a £700,000 Innovate UK grant — Emerald’s second award from the agency — and a further £700,000 in venture capital. The venture element was supported by Emerald’s existing investor base and new participants including Sequel and Highgoal. The company says its valuation has risen since the previous round.
Innovate UK’s grant is earmarked to support expansion of Emerald’s AI applications and core technology, with the stated aim of improving outcomes at scale across UK populations.
Chris Sawyer, Innovation Lead, Digital Health at Innovate UK, said:
Connecting earlier health insights with appropriate care is an important opportunity for healthcare innovation in the UK. Through this award, we are supporting Emerald’s development of AI-enabled technology designed to help clinicians deliver more personalised, proactive care. We look forward to seeing the project progress and the impact it could have on health outcomes.
If you're researching potential backers in this space:
- Explore our list of healthtech venture capital firms in the UK
- Browse our directory of healthtech angel investors in the UK
Founder perspective
Alexander Badalyan, Co-Founder and CEO of Emerald, set out the company’s rationale and ambition, arguing that testing alone is insufficient without clinical interpretation and follow-up.
Alexander Badalyan, Co-Founder and CEO of Emerald, said:
There’s huge demand for access to simple healthcare tools that move beyond just testing. People want to understand what those results mean and the steps they can take to boost their long-term health – informed by guidance from trusted medical experts.
A preventative approach to healthcare significantly improves long-term health outcomes by providing a more holistic view of a patient’s health, highlighting potential issues before they become critical, and empowering people to enter the right pathway earlier.
Achieving this ambition is a cornerstone of the current Government’s current health agenda – but the NHS cannot deliver this shift alone. Government efforts must be matched with innovative solutions that are able to have widespread reach. Emerald has unlocked access to millions of potential users through its partnerships – with ambitions to become the UK’s go-to platform for long-term health management. This additional funding allows us to build on the demand we’re already seeing, deepen these partnerships, and expand care.
The bigger picture
Emerald’s raise and Innovate UK backing underline ongoing public and private interest in preventative services and AI-enabled clinical tools. For employers and benefits providers, the proposition is clear: earlier detection plus integrated clinical pathways can reduce friction for employees seeking follow-up care. For investors, the combination of regulated clinical services and distribution partnerships creates a route to recurring revenue that is attractive in healthtech.
The deal also reflects policy priorities around prevention in the UK and the push for technology-enabled pathways to relieve pressures on NHS services. As Emerald scales its member base toward the stated target of one million users over three years, its progress will be a useful case study for how private platforms and public funding interact in the healthtech ecosystem.
Click here for a full list of 7,589+ startup investors in the UK